Investment Summary

Sphere Fluidics has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services. A novel technology platform called Cyto-MineTM enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes called picodroplets.

Uniquely, these systems enable the study of different, large biomolecules that interact with or are secreted by single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology. Exosomes, disease-related proteins, novel biomarkers and potential diagnostics, are also released from cells and should also be measurable in picodroplets. Sphere Fluidics’ technology enables study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains.